This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Fox, R. I. Articles by Kang, H.-I. Search for Related Content PubMed PubMed Citation Articles by Fox, R. I. Articles by Kang, H.-I. Social Bookmarking                         What's this?

Mechanism of Action of Antimalarial Drugs: Inhibition of Antigen Processing and Presentation

Department of Rheumatology, Scripps Clinic and Research Foundation, 10666 North Torrey Pines Road, La Jolla, California 92037, USA

Ho-Il Kang

Department of Rheumatology, Scripps Clinic and Research Foundation, 10666 North Torrey Pines Road, La Jolla, California 92037, USA

Recent studies have elucidated the steps involved in the association of antigenic peptides with major histocompatibility complex (MHC) encoded proteins and have suggested how antimalarial compounds might influence this important site of immune activation. These steps of antigen presentation in the macrophage (or other antigen-presenting cells) include: (a) the partial proteolytic degradation of endogenous and exogenous proteins into peptides within the lysosome; (b) the synthesis of MHC class II (i.e. HLA-D associated) , β, and invariant (Ii) chains in the endoplasmic reticulum; (c) the initial association of -Ii and β-Ii chains in the endoplasmic reticulum and the transport of these complexes to the primary endosome; (d) the fusion of lysosomal vacuoles and endosomal vacuoles, allowing the mixtures of lysosomal enzymes, peptides, -Ii and β-Ii; (e) the displacement of Ii chains by peptides to form -β-peptide complexes in the endosome; and (f) the migration of -β-peptide complexes to the macrophage cell surface where they can stimulate CD4 T cells, resulting in release of cytokines. A low pH is required for digestion of the protein by acidic hydrolases in the lysosome, for assembly of the -β-peptide complex and for its transport to the cell surface. Chloroquine and hydroxychloroquine are weak diprotic bases that can diffuse across the cell membrane and raise the pH within cell vesicles. This background provides the underlying basis for the theory that antimalarials may act to prevent autoimmunity by the following putative mechanism. Antimalarial compounds may: (a) stabilize the -Ii and β-Ii interactions and prevent low-affinity peptides from forming -β-peptide complexes; and (b) interfere with the efficient movement of -Ii, β-Ii and -β-peptide complexes to the correct locations within the cell cytoplasm or to the cell surfaces. Decreased presentation of autoantigenic peptides by macrophages might then lead to downregulation of autoimmune CD4 + T cells and diminish release of cytokines associated with clinical and laboratory signs of autoimmune disease.

Key Words: Hydroxychloroquine • Antimalarial • Antigen presentation • Autoimmunity

Lupus, Vol. 2, No. 1 suppl, S9-S12 (1993)
DOI: 10.1177/096120339300200103


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				M. Namazi The potential negative impact of proton pump inhibitors on the immunopharmacologic effects of chloroquine and hydroxychloroquine Lupus, February 1, 2009; 18(2): 104 - 105. [PDF]

				J Calvo-Alen, G McGwin, S Toloza, M Fernandez, J M Roseman, H M Bastian, E J Cepeda, E B Gonzalez, B A Baethge, B J Fessler, et al. Systemic lupus erythematosus in a multiethnic US cohort (LUMINA): XXIV. Cytotoxic treatment is an additional risk factor for the development of symptomatic osteonecrosis in lupus patients: results of a nested matched case-control study Ann Rheum Dis, June 1, 2006; 65(6): 785 - 790. [Abstract] [Full Text] [PDF]

				A Wozniacka, A Lesiak, J Narbutt, D P McCauliffe, and A Sysa-Jedrzejowska Chloroquine treatment influences proinflammatory cytokine levels in systemic lupus erythematosus patients Lupus, May 1, 2006; 15(5): 268 - 275. [Abstract] [PDF]

				K. T. Ho, C. W. Ahn, G. S. Alarcon, B. A. Baethge, F. K. Tan, J. Roseman, H. M. Bastian, B. J. Fessler, G. McGwin Jr, L. M. Vila, et al. Systemic lupus erythematosus in a multiethnic cohort (LUMINA): XXVIII. Factors predictive of thrombotic events Rheumatology, October 1, 2005; 44(10): 1303 - 1307. [Abstract] [Full Text] [PDF]

				A Wozniacka, A Carter, and D P Mccauliffe Antimalarials in cutaneous lupus erythematosus: mechanisms of therapeutic benefit Lupus, February 1, 2002; 11(2): 71 - 81. [Abstract] [PDF]

				M. Petri Hydroxychloroquine: past, present, future Lupus, February 1, 1998; 7(2): 65 - 67. [PDF]

				The Canadian Hydroxychloroquine Study Group, E Tsakonas, L Joseph, J M Esdaile, D Choquette, J-L Senecal, A Cividino, D Danoff, C K Osterland, C Yeadon, et al. A Long-Term Study of Hydroxychloroquine Withdrawal on Exacerbations in Systemic Lupus Erythematosus Lupus, February 1, 1998; 7(2): 80 - 85. [Abstract] [PDF]

				J. M. Esdaile The Efficacy of Antimalarials in Systemic Lupus Erythematosus Lupus, January 1, 1993; 2(1_suppl): S3 - S8. [Abstract] [PDF]